Biogen vs Moderna: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Biogen Inc (BIIB)

Q3 202629 Jun – 22 Sep 2026

▼3▲1

Biogen's mixed quarter: Leqembi approvals offset trial miss and guidance cut

Leqembi approvals expand access The FDA approved at-home subcutaneous Leqembi, and China and Japan approved injections, making the Alzheimer's drug easier to use. Leqembi sales rose 15% to about $184 million, helping Q2 results beat expectations.
This is a key positive development that drove investor optimism and revenue growth.
Diranersen trial failure Biogen's experimental drug diranersen missed its main trial goal, causing shares to drop 9%. This setback raised concerns about the company's pipeline and future growth prospects.
This was a major negative event that directly impacted the stock price.
Guidance cut on acquisition charges Biogen cut its 2026 earnings guidance to $12–$13 per share due to about $3.85 per share in acquisition charges, including from the $5.6 billion Apellis buyout. This lowered profit expectations.
The guidance cut is a significant negative factor that weighed on the stock.
Medicare pricing pressure on ZURZUVAE Medicare pricing pressure may limit the launch of ZURZUVAE, and Biogen is restricting it to a few European countries. This could slow the drug's uptake and revenue potential.
This highlights a regulatory and pricing challenge that could hinder growth.

August 202629 Jun – 22 Sep 2026

▲3▼1

Biogen expands Alzheimer's reach but pricing and competition weigh

RayThera acquisition adds immunology drug Biogen acquired RayThera, gaining an early-stage immunology drug. This adds a new potential treatment to its pipeline, showing progress in building future growth beyond its current medicines.
New acquisition expands pipeline, a key positive development in the period.
China and Japan approve at-home Leqembi injections China and Japan approved at-home under-the-skin Leqembi injections, making Alzheimer's treatment easier and expanding the market. This could boost sales and patient access in key regions.
Geographic expansion of Leqembi is a new positive catalyst for demand.
Ten Phase 3 programs promise growth Biogen has ten late-stage programs in development, which could drive future growth as its multiple sclerosis revenue shrinks. This shows a strong pipeline to replace older products.
Pipeline strength is a forward-looking positive not previously highlighted.
Medicare pricing pressure may limit ZURZUVAE launch Medicare pricing pressure could hurt the launch of ZURZUVAE, and Biogen is limiting it to a few European countries. This adds risk to a key new product's sales potential.
New pricing and launch risk for ZURZUVAE is a negative factor.

Latest29 Jun – 22 Sep 2026

▲3▼1

Biogen's pipeline push and Leqembi rollout drive gains, but pricing risks loom

10 Phase III programs signal growth beyond MS Biogen said it has 10 late-stage trials with results starting in Q4, shifting focus from its shrinking MS business to new drugs like LEQEMBI and ZURZUVAE. This raises hopes for future revenue growth, supporting the stock.
This is the main new strategic update that could drive long-term growth and investor optimism.
Japan approves at-home Leqembi injection Japan cleared a subcutaneous form of Leqembi, allowing weekly at-home dosing instead of hospital infusions. This is the third country to approve it, making the Alzheimer's drug easier to use and expanding its market, which could boost sales.
New regulatory approval directly expands the addressable market for a key growth drug.
Medicare price crackdown may limit Zurzuvae launch A study warns that U.S. efforts to align Medicare drug prices with cheaper countries could push companies to raise prices or withdraw medicines elsewhere. Biogen's CEO said Zurzuvae will launch in only a few European countries to offset lost U.S. revenue, signaling a hit to its global sales potential.
This is a new regulatory risk that could reduce future revenue from a key product.
Biogen posts best quarterly revenue beat in group Biogen's Q2 revenue of $2.74 billion rose 3.4% and beat expectations by 12.1%, the strongest among 11 therapeutics stocks. This shows better-than-expected commercial execution, which can lift investor confidence.
New earnings data confirms strong performance relative to peers, a positive fundamental signal.

6 Aug – 4 Sep 2026

▲3

Biogen's mixed quarter: raised revenue, cut EPS, new China approval

RayThera acquisition closes, EPS guidance cut Biogen completed its purchase of RayThera, adding an early-stage immunology drug. But acquisition charges forced it to slash 2026 adjusted EPS guidance to $12–$13 from $14.25–$15.25. The revenue outlook rose to mid-single-digit growth, but the profit hit is what investors will feel near-term.
This is the single biggest new event, directly changing Biogen's earnings outlook and explaining the stock's mixed reaction.
China approves at-home LEQEMBI injection China approved a subcutaneous (under-the-skin) form of LEQEMBI for early Alzheimer's, allowing weekly at-home dosing instead of hospital infusions. This is the second country to clear it, after the U.S. in July. It widens the market and makes treatment far easier for patients.
A new regulatory approval in a huge market (17 million early Alzheimer's patients in China) directly boosts the long-term sales potential of Biogen's key Alzheimer's drug.
Five Phase 3 readouts ahead; shares seen as undervalued Biogen raised its non-GAAP EPS guidance and has five late-stage trial results coming in lupus, transplant and rare diseases. Shares trade about 10% below the average analyst target, with a 54% one-year total return. But competition in MS and Alzheimer's, plus launch risks for LEQEMBI and ZURZUVAE, remain real concerns.
This gives the forward-looking catalyst picture and the valuation gap, which is central to why investors are watching Biogen now.
Biogen adopts Veeva's AI-powered CRM globally Biogen selected Veeva's Vault CRM suite, an AI-driven sales and safety platform, for global use. This is an operational upgrade, not a direct revenue driver, but it signals Biogen is investing in modern commercial infrastructure. It also deepens a multi-year software relationship, which can lower long-term selling costs.
It shows Biogen is modernizing its commercial operations with AI, a modest but real positive for efficiency and execution.

July 20262 Jul – 29 Jul 2026

▲2▼2

Biogen's mixed July: Leqembi wins, diranersen disappoints, guidance cut

FDA approves at-home subcutaneous Leqembi The FDA approved Leqembi Iqlik, an at-home under-the-skin version of Biogen's Alzheimer's drug. This should make treatment easier and more convenient, potentially boosting demand and future sales.
This is a new regulatory approval that could drive future revenue growth.
Q2 results beat on rare-disease and Leqembi demand Biogen's second-quarter results beat expectations, helped by strong demand for rare-disease drugs and Leqembi, with Leqembi sales up 15% to about $184 million. This shows the company's newer products are gaining traction.
This is new financial data showing better-than-expected performance.
Diranersen trial misses goal, shares drop 9% Biogen's experimental Alzheimer's drug diranersen missed its main trial goal, with a puzzling result: the lowest dose worked best while higher doses did worse. The failure sent shares down about 9%.
This is a major clinical setback that directly hurt the stock.
2026 earnings guidance cut on acquisition charges Biogen lowered its 2026 adjusted earnings forecast to $12–$13 per share from $14.25–$15.25, due to about $3.85 per share in acquisition charges, including 85 cents from the $5.6 billion Apellis buyout.
This is a new guidance cut that weighs on investor expectations.

2 Jul – 29 Jul 2026

▲3▼1

Biogen beats on drug demand but cuts 2026 profit outlook

Q2 beat on rare-disease and Leqembi demand Biogen's second-quarter profit and revenue beat expectations, helped by strong sales of rare-disease medicines and a 15% rise in Leqembi sales to about $184 million. This shows the core business is growing, which supports the stock.
This is the main new event of the period and directly explains why Biogen is moving.
2026 profit guidance cut on Apellis charges Biogen slashed its 2026 adjusted earnings forecast to $12–$13 per share from $14.25–$15.25, largely due to $3.85 per share of acquisition-related charges, including 85 cents from the $5.6 billion Apellis buyout. This weighs on the stock.
This is the key counterweight that explains why the stock isn't rising more despite the earnings beat.
Leqembi real-world data and sales momentum A real-world study showed over 75% of early Alzheimer's patients remained stable on Leqembi, and Q2 sales grew 43% excluding one-time stockpiling. This supports adoption and future sales, a positive for Biogen as Eisai's partner.
This new evidence reinforces the commercial case for Biogen's key Alzheimer's drug.
Pipeline progress: Gazyva priority review, litifilimab enrollment The FDA granted priority review to Gazyva for a rare kidney disease, and Biogen's lupus drug litifilimab completed Phase III enrollment with results due in H2 2026. These advance the pipeline and offer future growth, supporting the stock.
These are new regulatory and clinical milestones that add to the long-term growth story.

13 Jul – 15 Jul 2026

▲3▼1

Leqembi at-home approval lifts Biogen, but diranersen dosing flaw triggers sell-off

FDA approves at-home subcutaneous Leqembi The FDA approved Leqembi Iqlik, a once-weekly under-the-skin injection for early Alzheimer's, allowing at-home dosing. This removes the need for IV infusions, which should boost patient demand and sales. Biogen shares rose on the news.
This is a major new approval that directly expands the market for Biogen's key Alzheimer's drug.
Diranersen shows 42% cognitive decline slowdown Biogen presented Phase 2 data showing its tau-targeting drug diranersen slowed cognitive decline by 42% on one measure and cut tau tangles. This suggests a potential new Alzheimer's treatment, lifting hopes for future growth.
Positive efficacy data from a new drug candidate is a key driver of investor optimism.
Dosing paradox clouds diranersen data, stock tumbles The same Phase 2 trial missed its main goal because the lowest dose worked best while higher doses did worse. This unexplained 'dosing paradox' raised doubts about the drug's effectiveness and path forward, causing Biogen shares to fall nearly 9%.
This negative twist directly caused a sharp sell-off and creates uncertainty about a key pipeline asset.
Truist upgrade highlights Alzheimer's pipeline A Truist analyst upgrade pointed to optimism for Biogen's Alzheimer's pipeline, helping the stock gain even as the broader market fell. This analyst view reinforced positive sentiment around the company's Alzheimer's efforts.
Analyst upgrade is a fresh catalyst that supported the stock price during the period.

Q2 202617 Jun – 26 Jun 2026

▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.
This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.
FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.
This is a new regulatory win that supports the bull case for Biogen's pipeline.
Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.
This is a new negative event that introduces regulatory and legal uncertainty.
Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.
This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

June 202617 Jun – 26 Jun 2026

▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.
This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.
FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.
This is a new regulatory win that supports the bull case for Biogen's pipeline.
Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.
This is a new negative event that introduces regulatory and legal uncertainty.
Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.
This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

17 Jun – 26 Jun 2026

▲2▼2

Biogen buys RayThera, wins FDA tag, but legal probe and legacy decline weigh

RayThera acquisition expands immunology pipeline Biogen agreed to buy private biotech RayThera for up to $1 billion, mostly in future milestone payments. This adds early-stage anti-inflammatory drugs to its pipeline, a bet on future growth. Investors liked the move, helping push the stock up.
This is the main new event driving positive sentiment and shows Biogen's strategy to replace lost revenue.
FDA Breakthrough Therapy designation for Salanersen Biogen's spinal muscular atrophy drug candidate Salanersen received FDA Breakthrough Therapy status, which speeds up development and review. This signals the drug may be effective and could become a future growth driver, boosting investor confidence.
This is a new regulatory win that supports the bull case for Biogen's pipeline.
Securities fraud investigation over CELIA study Law firm Pomerantz is investigating Biogen for possible securities fraud related to its Phase 2 CELIA study, which missed its main goal but was described positively. This legal risk could lead to fines or lawsuits, weighing on the stock.
This is a new negative event that introduces regulatory and legal uncertainty.
Legacy drug sales decline continues to drag Biogen's older multiple sclerosis drugs and Spinraza are losing sales to generics and rivals. Newer drugs are growing but not fast enough to fully offset the decline. This ongoing pressure limits overall revenue growth and keeps a lid on the stock.
This is a key fundamental challenge that offsets positive pipeline news and explains why the stock isn't higher.

Moderna Inc (MRNA)

Q3 202622 Jun – 2 Oct 2026

▲3▼1

Moderna hits four-year high on vaccine wins, but risks mount

FDA approves mRNA flu vaccine Moderna's mRNA flu vaccine, mFLUSIVA, won FDA approval, opening a new revenue stream and boosting investor confidence in the company's mRNA platform beyond COVID.
This is a major new product approval that directly drove the stock higher.
Melanoma vaccine Phase 3 win A Phase 3 trial of Moderna's melanoma cancer vaccine with Merck succeeded, briefly sending shares up 177% and validating its personalized cancer vaccine approach.
This is a significant clinical milestone that excited investors about future revenue.
Nasdaq 100 inclusion and UAE talks Moderna joined the Nasdaq 100 index and held investment talks with the UAE, adding momentum as index funds bought shares and international interest grew.
These events increased demand for the stock and broadened its investor base.
Setbacks and dilution weigh Vaccine skepticism caused an 11% one-day drop, norovirus trials failed, and a $2.6 billion convertible note raise diluted shareholders, while patent settlements and a Citi downgrade added pressure.
These negative developments created real counterweights to the positive news.

September 202622 Sep – 2 Oct 2026

▲2▼2

Moderna hits 4-year high on UAE talks, Nasdaq 100 entry; Citi downgrade and patent suit weigh

UAE investment and manufacturing talks Moderna's chairman met UAE officials to discuss investment and pharma manufacturing cooperation. This could fund expansion and open a new market, pushing the stock to a four-year high of $195.71. It shows the company is building beyond COVID.
New event that directly lifted the stock to a multi-year high and signals growth beyond COVID.
Nasdaq 100 index inclusion Moderna will join the Nasdaq 100 on October 9, replacing Warner Bros. Discovery. Index funds that track the Nasdaq 100 must buy the stock, creating automatic demand. This often lifts a stock's price and adds credibility.
New event that creates forced buying by index funds, a direct positive for the stock price.
Citi downgrade to sell on valuation Citi downgraded Moderna to sell, saying the stock's valuation is unjustifiable after the cancer vaccine win. The price target is 60% below the prior close. This warns that the stock may have run too far, too fast, and it fell over 6%.
New analyst action that directly pushed the stock down and highlights valuation risk.
Monsanto mRNA patent lawsuit proceeds A judge rejected Moderna's bid to dismiss Monsanto's patent infringement lawsuit over its COVID vaccine. The case will continue, creating legal uncertainty and potential financial liability. This is a real counterweight to the recent good news.
New legal development that adds uncertainty and potential cost, weighing on the stock.

Latest22 Sep – 2 Oct 2026

▲2▼2

Moderna hits 4-year high on UAE talks, Nasdaq 100 entry; Citi downgrade and patent suit weigh

UAE investment and manufacturing talks Moderna's chairman met UAE officials to discuss investment and pharma manufacturing cooperation. This could fund expansion and open a new market, pushing the stock to a four-year high of $195.71. It shows the company is building beyond COVID.
New event that directly lifted the stock to a multi-year high and signals growth beyond COVID.
Nasdaq 100 index inclusion Moderna will join the Nasdaq 100 on October 9, replacing Warner Bros. Discovery. Index funds that track the Nasdaq 100 must buy the stock, creating automatic demand. This often lifts a stock's price and adds credibility.
New event that creates forced buying by index funds, a direct positive for the stock price.
Citi downgrade to sell on valuation Citi downgraded Moderna to sell, saying the stock's valuation is unjustifiable after the cancer vaccine win. The price target is 60% below the prior close. This warns that the stock may have run too far, too fast, and it fell over 6%.
New analyst action that directly pushed the stock down and highlights valuation risk.
Monsanto mRNA patent lawsuit proceeds A judge rejected Moderna's bid to dismiss Monsanto's patent infringement lawsuit over its COVID vaccine. The case will continue, creating legal uncertainty and potential financial liability. This is a real counterweight to the recent good news.
New legal development that adds uncertainty and potential cost, weighing on the stock.

August 202622 Jun – 17 Sep 2026

▲2▼2

Moderna's mRNA flu and cancer wins drive huge but volatile August

FDA approves first mRNA flu vaccine The FDA approved mFLUSIVA, Moderna's mRNA flu vaccine, adding a fifth commercial product and validating the platform beyond COVID. This opened a new revenue stream and boosted investor confidence.
This is a major new approval that directly expands Moderna's product portfolio and revenue potential.
Cancer vaccine Phase 3 win with Merck Moderna and Merck's mRNA cancer vaccine intismeran succeeded in a Phase 3 melanoma trial, sending MRNA up as much as 177%. Analysts raised targets, with peak sales forecasts up to $54 billion.
This is a landmark clinical win that opens a massive new market and was the primary driver of the stock's surge.
Norovirus failure and patent payment Moderna's norovirus vaccine failed a Phase 3 interim goal, and the company paid $178 million to settle a patent dispute with Arbutus. These added pipeline uncertainty and legal costs.
These setbacks weighed on sentiment and highlighted pipeline and legal risks.
Dilution and competitive setback Moderna raised $2.6 billion in convertible notes, diluting shareholders and pressuring the stock. BioNTech's colorectal cancer trial failure created negative read-across, and MRNA pulled back 20–23% after its surge.
These factors contributed to the sharp pullback and reflect financing and competitive risks.

22 Jun – 17 Sep 2026

▲4

Moderna's mRNA platform broadens beyond COVID as cancer and flu advance

FDA panel backs mRNA flu shot An FDA advisory panel voted unanimously that Moderna's mRNA flu shot, mFlusiva, is safe and effective for adults 50 and older. This clears a key regulatory hurdle and opens a second big market beyond COVID, supporting the stock.
This is a new regulatory milestone that expands Moderna's commercial opportunity.
Bird flu vaccine enters Phase 3 Moderna started a late-stage trial of its mRNA bird flu vaccine with backing from an international pandemic group. It shows the mRNA platform can target new infectious diseases, adding another potential long-term growth driver.
This is a new pipeline advancement that broadens the platform's application.
Cancer vaccine Phase 3 success confirmed Moderna and Merck's personalized mRNA cancer vaccine met its main goal in a large melanoma trial, cutting recurrence risk. This is the first late-stage win for an mRNA cancer therapy, opening a potential multi-billion-dollar market and driving the stock sharply higher.
This is the core new event that re-rates Moderna's growth story.
Stock extends rally on cancer data MRNA jumped 6% to $154, extending a 137% one-month rally, as investors continued to bet on the melanoma vaccine data. No new company news drove the move, but the market is rewarding Moderna's specific cancer asset over rivals.
This shows the market's ongoing positive reaction to the cancer vaccine news.

30 Aug – 2 Sep 2026

▲3

Moderna's mRNA platform wins fresh validation as cancer and flu shots advance

FDA approves updated COVID and first mRNA flu shots Moderna won FDA approval for updated Spikevax and mNEXSPIKE COVID vaccines and mFlusiva, the first mRNA flu shot for adults 50+. This expands its sellable respiratory portfolio, though annual uptake and pricing will decide how much it really adds.
New regulatory approvals directly expand Moderna's product lineup and revenue potential.
GSK's mRNA flu vaccine advance validates platform GSK said it will move its mRNA flu vaccine into Phase III after positive Phase II results. Investors saw this as proof that mRNA works for flu, not as a threat, and Moderna shares rose nearly 10% on the news.
A rival's progress independently validates the mRNA platform Moderna is built on.
August surge and $2B raise show investor conviction Moderna ended August up 156%, the top S&P 500 performer, after the melanoma trial win. It also raised $2 billion in convertible notes for its cancer vaccine business, and hedge fund holdings rose 10% to $1.5 billion.
Confirms the cancer breakthrough is translating into real capital and sustained investor backing.

19 Aug – 28 Aug 2026

▲2▼1

Moderna's cancer vaccine win reshapes growth story; $2.6B raise and BioNTech stumble add caution

First mRNA cancer vaccine clears Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a 1,137-patient melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.
This is the single biggest new event of the period and the core reason MRNA moved.
Analyst upgrades and huge sales forecasts William Blair upgraded Moderna to Outperform and Wolfe Research to peer perform, while forecasts for intismeran peak sales range from $1.4 billion (Leerink) to $16.8 billion (Morningstar) by 2035. These signal professional investors see the cancer win as a durable business driver, not just a one-day pop.
Upgrades and forecasts show whether the cancer win is treated as lasting value, which drives the stock beyond the initial spike.
$2.6B convertible note raise dilutes and pressures stock Moderna plans to raise $2.6 billion via convertible notes due 2032 for its cancer vaccine business and debt repayment. Convertible notes can dilute existing shareholders if converted, and the stock fell about 5% premarket and 4% intraday on the news, a real counterweight to the rally.
This is the main new negative force this period and explains why MRNA fell for three straight sessions.
BioNTech's trial failure cuts both ways BioNTech halted a Phase 2 mRNA cancer vaccine trial in colorectal cancer for futility, sending its shares down 10% and dragging Moderna lower on negative read-across. But the failure also highlights Moderna's melanoma success, where it targeted a 'hot' tumor with Keytruda, strengthening its competitive position.
This is a new event that both pressures MRNA via sector sentiment and supports its relative advantage.

19 Aug – 21 Aug 2026

▲2▼1

Moderna's mRNA cancer vaccine clears Phase 3, reshaping growth story

First mRNA cancer vaccine wins Phase 3 Moderna and Merck's personalized mRNA cancer vaccine, intismeran, met its main goal in a large melanoma trial, cutting recurrence versus Keytruda alone. This is the first late-stage win for an mRNA cancer therapy, opening a potential new market beyond vaccines and sending MRNA up as much as 177%.
This is the core new event that explains the period's massive move and changes Moderna's long-term growth story.
Analysts upgrade and raise sales forecasts BofA upgraded Moderna to Neutral with a $170 target and lifted its peak sales estimate for intismeran to $54 billion, while William Blair moved to Outperform. These upgrades signal that professional investors see the cancer win as a real, durable business driver, not just a one-day pop.
Analyst upgrades and raised forecasts show the market is repricing Moderna's future revenue, which supports the stock beyond the initial spike.
Sharp pullback after record surge After the record 177% jump, MRNA fell about 20-23% the next day as some investors took profits. Such a violent swing shows the stock is now very volatile and that not everyone believes the rally is justified, which can scare off cautious investors.
The pullback is a real counterweight to the positive news and shows the risk that the stock has run far ahead of fundamentals.
Valuation gap and short-seller pain Even after the surge, the average analyst price target is only about $44, far below the last close near $133, suggesting the stock may be overvalued. Short sellers lost about $5.5 billion, which can fuel further sharp moves in either direction as positions unwind.
This highlights the tension between the exciting science and the stock's stretched valuation, a key risk for new investors.

3 Aug – 12 Aug 2026

▲2▼2

Moderna wins first mRNA flu vaccine approval, but norovirus trial fails

FDA approves first mRNA flu vaccine Moderna won FDA approval for mFLUSIVA, the first mRNA-based flu vaccine, for adults 50 and older. This is a major milestone: a new product to sell and proof its mRNA technology works beyond COVID, which can lift the stock.
This is the biggest new event, directly adding a new product and validating the platform.
Norovirus vaccine fails interim analysis Moderna's norovirus vaccine candidate did not meet early success criteria in a Phase 3 interim analysis, and the company will enroll more patients. This is a pipeline setback that can weigh on the stock by raising doubts about other vaccine programs.
This is a new negative event that offsets the flu approval and affects pipeline sentiment.
Ebola vaccine trial starts Moderna began a Phase 1 trial of an Ebola vaccine for a strain with no approved shot, backed by up to $50 million from CEPI. It shows the mRNA platform can target new diseases, supporting the long-term growth story even if revenue is years away.
This is a new pipeline milestone that broadens the platform's potential beyond COVID and flu.
Arbutus settlement payment Arbutus received a $178 million payment from Moderna as part of a $950 million patent settlement. This is cash leaving Moderna and a reminder that legal costs from past patent disputes continue to weigh on finances.
This is a new cash outflow event that affects Moderna's financial position.

July 202629 Jun – 31 Jul 2026

▲2▼2

Moderna hits 52-week high on analyst upgrades and pipeline progress

Analyst upgrades and Science Day lift shares Piper Sandler raised its price target and Jim Cramer turned positive, while Science Day showcased expansion into cancer, autoimmune treatments, and in vivo CAR-T, pushing shares to a 52-week high.
This explains the main positive driver of the stock's rise during the period.
Q2 beat and flu vaccine decision ahead Q2 results beat estimates with reaffirmed guidance, and an FDA decision on the mRNA-1010 flu vaccine is due August 5, potentially adding a fifth commercial product.
This highlights fundamental strength and a near-term catalyst that supported the stock.
Vaccine skepticism triggers sharp drop Renewed vaccine skepticism caused an 11% one-day drop, showing political and public sentiment risks can still pressure the stock despite improving fundamentals.
This is a key counterweight that pulled the stock down during the period.
Patent settlement and norovirus setback Moderna paid $178 million to Arbutus in a patent settlement, and its norovirus vaccine trial missed an early goal, adding legal costs and pipeline uncertainty.
These setbacks weighed on the stock and show ongoing legal and pipeline risks.

22 Jul – 31 Jul 2026

▲3▼1

Moderna beats Q2, flu shot decision looms, norovirus trial stumbles

Q2 earnings beat and outlook reaffirmed Moderna beat second-quarter revenue and loss estimates and reaffirmed its full-year growth target. This shows the business is performing better than expected, which supports the stock price by reducing fears about cash burn and future funding needs.
This is the main new financial event of the period and directly affects investor confidence in MRNA.
FDA decision on mRNA-1010 flu vaccine due August 5 An FDA ruling on Moderna's standalone flu shot is expected within days. Approval would give Moderna a fifth commercial product and help rebuild its respiratory vaccine business, potentially lifting the stock if the decision is positive.
This is a near-term regulatory catalyst that could significantly change MRNA's product lineup and revenue outlook.
Norovirus vaccine trial misses early metric Moderna's norovirus vaccine trial missed an early goal, disclosed alongside earnings. This is a setback for a pipeline candidate and may dampen enthusiasm about the company's broader vaccine prospects, weighing on the stock.
This is a new negative development that tempers the positive earnings news and highlights pipeline risk.
Strong Q1 revenue growth and AI ranking Moderna's Q1 revenue surged 260% year-over-year, the fastest among therapeutics stocks, and it ranked third in an investor survey of AI integration. These reinforce the growth narrative and positive sentiment, though the AI angle is not a major valuation driver.
This provides context on Moderna's recent financial momentum and investor perception, supporting the bull case.

29 Jun – 16 Jul 2026

▲2▼2

Moderna's mRNA pipeline wins fans, but political and legal clouds linger

Analyst upgrade and Cramer's bullish turn Piper Sandler raised its price target, and Jim Cramer said Moderna is investable again, citing the pipeline shift into cancer, rare diseases, and a new flu shot. These endorsements drew new buyers, pushing the stock up sharply.
New analyst and media endorsements directly lifted investor sentiment and the stock price.
Science Day fuels mRNA expansion hopes Moderna's Science Day showcased plans to move beyond vaccines into cancer therapies, autoimmune treatments, and an in vivo CAR-T candidate. Investors saw a broader future beyond COVID, driving the stock to a 52-week high and adding billions in market value.
The Science Day event was a major catalyst that expanded the growth story and attracted investors.
Vaccine skepticism resurfaces Renewed political focus on vaccine skepticism sent Moderna shares down nearly 11% in one day. This shows that political and public-health headwinds can still hit the stock hard, even as the pipeline improves.
This is a new negative development that highlights a real risk to Moderna's core vaccine business.
Patent settlement cash outflow Moderna paid $178 million to Arbutus as part of a patent settlement. While the amount is smaller than earlier settlements, it is still cash out the door and a reminder that legal costs continue to weigh on finances.
This new payment is a concrete financial hit and shows ongoing litigation costs.

Q2 202617 Jun – 26 Jun 2026

▲3▼1

Moderna's Flu Vaccine Wins FDA Panel, but Patent Settlement Weighs

FDA panel backs mRNA flu vaccine An FDA advisory panel unanimously recommended Moderna's mRNA flu vaccine for adults 50 and older, making approval likely in August and opening a new revenue stream.
This is a major new regulatory milestone that could add a new product to Moderna's lineup.
Pipeline expansion and Science Day Moderna plans three vaccine launches by 2028 and showcased cancer, autoimmune, and rare disease programs at its Science Day, boosting investor confidence in its long-term pipeline.
This highlights new growth opportunities beyond COVID, which is key to the investment case.
Q1 revenue surges 260% First-quarter revenue jumped 260% to $389 million, beating analyst estimates, showing a strong rebound in sales.
This is a new financial result that demonstrates improving business performance.
Patent settlement costs $2.25 billion Moderna must pay $2.25 billion to settle patent litigation with Roivant, reducing its financial flexibility and adding a significant cash outflow.
This is a new negative event that could strain Moderna's finances and limit its ability to invest.

June 202617 Jun – 26 Jun 2026

▲3▼1

Moderna's Flu Vaccine Wins FDA Panel, but Patent Settlement Weighs

FDA panel backs mRNA flu vaccine An FDA advisory panel unanimously recommended Moderna's mRNA flu vaccine for adults 50 and older, making approval likely in August and opening a new revenue stream.
This is a major new regulatory milestone that could add a new product to Moderna's lineup.
Pipeline expansion and Science Day Moderna plans three vaccine launches by 2028 and showcased cancer, autoimmune, and rare disease programs at its Science Day, boosting investor confidence in its long-term pipeline.
This highlights new growth opportunities beyond COVID, which is key to the investment case.
Q1 revenue surges 260% First-quarter revenue jumped 260% to $389 million, beating analyst estimates, showing a strong rebound in sales.
This is a new financial result that demonstrates improving business performance.
Patent settlement costs $2.25 billion Moderna must pay $2.25 billion to settle patent litigation with Roivant, reducing its financial flexibility and adding a significant cash outflow.
This is a new negative event that could strain Moderna's finances and limit its ability to invest.

20 Jun – 26 Jun 2026

▲3

Moderna's pipeline beyond COVID wins investor confidence

Science Day showcases pipeline beyond COVID Moderna's Science Day highlighted progress in cancer, autoimmune, and next-generation mRNA treatments, including its first cancer prevention program and a multiple sclerosis therapy. This expands the company's potential beyond COVID vaccines, giving investors new reasons to believe in future growth and pushing the stock up.
This is the main new event of the period and directly explains the stock's surge.
FDA panel backs flu vaccine, approval decision in August An FDA advisory panel voted 9-0 in favor of Moderna's mRNA flu vaccine for adults 50 and older, making final approval by August 5 much more likely. A new revenue stream would reduce reliance on COVID vaccines, boosting investor optimism and the stock price.
This is a new regulatory milestone that de-risks a key product and supports the stock's rise.
Strong Q1 revenue growth beats expectations Moderna's first-quarter revenue jumped 260% year over year to $389 million, beating analyst estimates by 55.8%. This shows the business is growing faster than expected, which supports the stock price even though the company still posted a loss.
This new earnings data provides fundamental support for the stock's recent gains.
Analysts still cautious despite strong run Even after the stock surged nearly 42% in a month, Quant Ratings, Seeking Alpha analysts, and Wall Street analysts maintain a Hold rating. This suggests that while the pipeline is promising, significant risks remain, which could limit further upside or lead to pullbacks.
This provides a fair counterweight to the positive news and explains why the stock isn't rated a buy.

17 Jun – 18 Jun 2026

▲2▼1

Moderna's flu vaccine wins FDA panel backing, but patent settlement costs $2.25B

FDA panel unanimously backs Moderna's flu vaccine An FDA advisory committee voted 9-0 that Moderna's mRNA flu vaccine is safe and effective for adults 50 and older. This key endorsement makes approval by the August 5 deadline much more likely, opening a new revenue stream and boosting investor confidence.
This is the main new event that directly lifts MRNA's price by de-risking a major product approval.
Moderna plans three new vaccine launches by 2028 Moderna said it will launch a combined flu-COVID shot, a seasonal flu vaccine, and a norovirus vaccine between 2027 and 2028. It also expects important trial results this year for a personalized cancer therapy and a rare disease treatment, which could lead to its first oncology and rare disease products.
This new pipeline update shows future growth beyond COVID vaccines, supporting a higher stock price.
Moderna to pay $2.25 billion in patent settlement Moderna agreed to a $2.25 billion global settlement with Roivant Sciences to resolve patent-infringement litigation. This is a large cash outflow that reduces Moderna's financial flexibility and is a real cost, even though it removes a legal cloud.
This new settlement is a significant negative financial event that weighs on MRNA's price.